Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Clinical value of ultradeep HIV-1 genotyping and tropism testing in late presenters with advanced disease.

AIDS (London, England) - 31 Jul 2015

Casadellà Maria, Manzardo Christian, Noguera-Julian Marc, Ferrer Elena, Domingo Pere, Pérez-Álvarez Susana, Podzamczer Daniel, Plana Montserrat, Clotet Bonaventura, Gatell José M, Miró José M, Paredes Roger

Abstract excerpt

OBJECTIVE: This article aims to investigate if the detection of preexisting drug-resistant minority variant (DRMV) and/or X4 HIV-1 variants could improve the efficacy of first-line combined antiretroviral therapy (ART) in late presenters. DESIGN: Post-hoc, combined analysis of two open-label, prospective, randomized clinical trials comparing first-line ART with efavirenz (EFV) vs. ritonavir-boosted protease...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Anti-Retroviral Agents
Share to Antiretroviral Therapy, Highly Active

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Drug Resistance, Viral

Share to Genotyping Techniques

Share to HIV Infections

Share to Treatment Outcome

Share to Viral Tropism

Source

Identifiers

PMID: 26244389
DOI: 10.1097/QAD.0000000000000748

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Clinical value of ultradeep HIV-1 genotyping and tropism testing in late presenters with advanced disease.PMID 26244389Read ↗

Primary HIV-1 Drug Resistant Minority Variants.Semantic proximity Read ↗

Clinical impact of ultra deep versus Sanger sequencing detection of minority mutations on HIV-1 drug resistance genotype interpretation after virological failureSemantic proximity Read ↗

Next-Generation Sequencing Reveals a High Frequency of HIV-1 Minority Variants and an Expanded Drug Resistance Profile among Individuals on First-Line ART.Semantic proximity Read ↗

Added value of deep sequencing relative to population sequencing in heavily pre-treated HIV-1-infected subjects.Semantic proximity Read ↗

Low-frequency drug-resistant HIV-1 and risk of virological failure to first-line NNRTI-based ART: a multicohort European case-control study using centralized ultrasensitive 454 pyrosequencing.Semantic proximity Read ↗

The Role of HIV-1 Drug-Resistant Minority Variants in Treatment FailureSemantic proximity Read ↗

Low-Abundance Drug-Resistant HIV-1 Variants in Antiretroviral Drug-Naive Individuals: A Systematic Review of Detection Methods, Prevalence, and Clinical Impact.Semantic proximity Read ↗

Impact of Human Immunodeficiency Virus Type 1 Minority Variants on the Virus Response to a Rilpivirine-Based First-line Regimen.Semantic proximity Read ↗

Next Generation Sequencing Reveals a High Prevalence of HIV-1 Minority Variants and an Expanded Drug Resistance Profile Among Individuals Initiated to Antiretroviral Therapy in a Resource-constrained SettingSemantic proximity Read ↗

Pre-treatment minority HIV-1 drug resistance mutations and long term virological outcomes: is prediction possible?Semantic proximity Read ↗

Rare HIV-1 transmitted/founder lineages identified by deep viral sequencing contribute to rapid shifts in dominant quasispecies during acute and early infectionSemantic proximity Read ↗

Minority variants of drug-resistant HIV.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.